fonda, page-4

Revenues from North America for Q3 FY13 at Rs.9.2 billion ($178 Mn), recorded YoY growth of 38%#. ? Growth is largely driven by key limited competition products of ziprasidone, tacrolimus, fondaparinux and ramp-up in antibiotics portfolio.

While improvement in market share of key products (total prescription share in fondaparinux has improved to 18 per cent now) will help the company register growth, upcoming blockbuster generic launches including Lipitor, Plavix, Seroquel, Actos and Geodon too could provide it growth opportunities.